ATAI LIfe Sciences is about to add three new R&D partners to its industry-leading psychedelics research platform.
Science Reveals The Cannabis Industry’s Greatest Lie: You’re Buying Weed Wrong (And So Is Everyone Else)
There’s much more to cannabis than THC—for solid proof, look no further than the CBD boom—but when it comes to moving product on the legal recreational market, only two numbers matter: the list price, and the THC content.
Proof Of Marijuana Use Discovered At Ancient Biblical Site In Israel
An ancient biblical tribe in Israel likely used marijuana to produce hallucinogenic effects as part of cultic rituals, according to a new study that identified cannabis resin on an alter in a shrine built around 750 BCE.
Do Highly Potent MJ Concentrates Get Users More High? Not Exactly, Study Finds
High-potency marijuana concentrates on today’s legal markets can contain upwards of 90 percent THC, so one might reasonably expect them to pack a greater psychoactive punch than typical flower, which tops out around 30 percent.
MindMed To Evaluate Ayahuasca's Active Ingredient DMT In A Phase 1 Clinical Trial Collaboration
MindMed is adding to its psychedelics clinical trials
Red Light Holland Announces the Closing of Second Tranche of Private Placement
With the closing of its second tranche, Red Light Holland has now raised CAD$3,830,529 in its latest financing.
Champignon Provides Corporate Update, Announces Name Change, Rebranding and Planned Spin Out
Champignon Brands is proposing changing its name to Apotheosis Scientific and announces a planned spin-off of its consumer packaged goods (CPG) division.
Why is it so hard for medical cannabis patients to get high?
Once upon a time, I was a one-hit wonder. Just one inhale would render a dull day into one that was endlessly entertaining.
Numinus receives Health Canada licence amendment to produce and extract psilocybin from mushrooms
Numinus becomes the first publicly traded company in Canada to obtain such licensing for psychedelics research.
Will Compass Pathways Be The Next Unicorn?
As rumors swirl about Compass Pathways going public, this could become the first psychedelics Unicorn.
MindMed Begins Phase 2 Clinical Trial of LSD for Treating "Suicide Headaches"
MindMed begins a Phase 2 clinical trial of LSD for cluster headaches in Switzerland.
